Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: POLBF )

0.1150 UNCHANGED
Last Price Updated: 9:30 AM EST, Feb 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about POLBF

< Previous 1 2 Next >
Poolbeg Pharma PLC Announces Directorate Change
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Immunomodulator II Patent Granted in Japan
Via ACCESSWIRE
Poolbeg Pharma PLC Announces POLB 001 LPS Trial Data to be Presented at IUIS
Via ACCESSWIRE
Former Amryt Pharma Leadership Team join Poolbeg
Via ACCESSWIRE
Poolbeg Pharma PLC Announces POLB 001 Data to be Presented at American Society of Hematology Annual Meeting
Via ACCESSWIRE
Poolbeg Pharma PLC Announces POLB 001 Oncology Programme Update Meeting
Via ACCESSWIRE
Poolbeg Partners with a Nasdaq-Listed Biopharma
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Favourable Conclusion of Patent Opposition
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Immunomodulator I Patent Opposition Withdrawal
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Interim Results for the Six Months to 30 June 2023
Via ACCESSWIRE
Poolbeg Pharma unveils new collaboration agreement
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Thomas Warner from Proactive after announcing the pharma & biotech company has signed a new collaboration agreement with an... 
Via TheNewswire.com
Poolbeg Pharma "moving forward rapidly" with POLB001
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Thomas Warner from Proactive after announcing the pharma & biotech's interim results for the six months to 30 June 2023.... 
Via TheNewswire.com
Topics Artificial Intelligence
Exposures Artificial Intelligence
Poolbeg Pharma and CytoReason identify "very exciting influenza targets"
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington and CytoReason co-founder and CEO David Harel speak to Thomas Warner from Proactive after announcing what they call a "significant... 
Via TheNewswire.com
Topics Artificial Intelligence
Exposures Artificial Intelligence
Poolbeg Pharma PLC Announces AI Led Programme Identifies Influenza Drug Targets
Via ACCESSWIRE
Poolbeg Pharma PLC - Oral Vaccine Programme Moves Forward
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Annual Report & AGM Notice
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Results for the Year Ended 31 December 2022
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Strategic Expansion of POLB 001 into Oncology
Via ACCESSWIRE
Poolbeg Pharma sees "significant commercial opportunity" in oral vaccines
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Thomas Warner from Proactive after announcing that work on the company's Oral Vaccine Programme collaboration is now set to... 
Via TheNewswire.com
Poolbeg Pharma PLC Announces Board Appointment
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Results of Annual General Meeting
Via ACCESSWIRE
Poolbeg Pharma "in a very healthy cash position" after first full year of operations
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after publishing final results for 2022 that show that the clinical-stage biotech company finished its first full... 
Via TheNewswire.com
Poolbeg Pharma PLC Announces Positive Initial Data Analysis in POLB 001 Trial
Via ACCESSWIRE
Poolbeg Identifies Novel RSV Drug Candidates
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Metabolic Diseases Oral Delivery Licence Signed
Via ACCESSWIRE
Proactive's Robin Davison publishes fresh research note on Poolbeg Pharma
Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new report on Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF), following the release of selected data from its human... 
Via TheNewswire.com
Poolbeg Pharma "couldn't be happier" with POLB 001 human challenge trial data
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive's Thomas Warner after announcing the data readout from an LPS human challenge trial for POLB 001, the infectious... 
Via TheNewswire.com
Poolbeg Pharma "really open" to different types of deal for POLB 001
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) VP of Business Development David English speaks to Proactive's Thomas Warner about the work he's doing to progress the clinical stage infectious disease... 
Via TheNewswire.com
Poolbeg Pharma announces expansion of POLB 001 into oncology
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive's Thomas Warner after announcing that the company has submitted a patent application for the use of POLB 001 in a... 
Via TheNewswire.com
Topics Intellectual Property
Exposures Intellectual Property
Poolbeg Pharma upbeat on preliminary influenza drug results
Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential... 
Via TheNewswire.com
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.